The health care setting rather than medical speciality impacts on physicians adherence to guideline-conform anticoagulation in outpatients with non-valvular atrial fibrillation: a cross sectional survey
© Gerber et al; licensee BioMed Central Ltd. 2012
Received: 28 June 2011
Accepted: 29 February 2012
Published: 29 February 2012
In patients with non-valvular atrial fibrillation (NVAF) at high risk for stroke guidelines consistently recommend long-term oral anticoagulation (OAC) with a vitamin K antagonist. However recommendations remain ambiguous in respect to the precise OAC initiation regimens. Based on the clinical observation, that the initiation of OAC for NVAF varies considerably in daily practice, we aimed to assess the current practice in Switzerland.
Cross-sectional survey of randomly selected general practitioners, internists and cardiologists from different health care settings in an urban Swiss region that covers 1.4 million inhabitants. The main outcome measures were the preferred antithrombotic initiation regimen and long-term treatment in patients with newly diagnosed NVAF at high risk for stroke.
We received 226 out of 388 (58.2%) surveys. Compared to physicians working in a hospital setting (33.6% of respondents) physicians in ambulatory care reported more years of experience and claimed lower-use (never or seldom) of guidelines in general (47.6 vs. 12.2%). Regarding long-term thromboembolic prophylaxis 93.7% of all responders followed current recommendation by choosing an OAC. When focussing on guideline-consistent correct OAC initiation (either low-dose initial OAC or a combination of LMWH and OAC) adherence dropped to 60.6% with hospital physicians demonstrating a significantly higher use of guideline-conform OAC regimens (79.7 vs. 51.0%). Medical speciality in non-hospital physicians was not related to correct guideline-use. Hospital setting remained independently associated with a guideline-conform OAC initiation regimen (OR 2.8, p = 0.023) when controlled for medical speciality, physicians' characteristics and clinical experience. Problems when starting an anticoagulation treatment were seldom reported (never or seldom accounting for 94.1% of all responses).
The guideline adherence with respect to OAC initiation regimens in NVAF was significantly lower when compared to long-term treatment and health care setting rather than medical speciality explained guideline-conform OAC initiation. The majority of the physicians did not consider the initiation of anticoagulation to be a major obstacle in outpatient care.
Even though actual guidelines provide clear-cut recommendations regarding the long-term stroke prophylaxis in non-valvular atrial fibrillation (NVAF), they tend to remain somewhat ambiguous with respect to the initiation regimens for oral anticoagulation (OAC) [1, 2]. Several guidelines allow initiation with low-dose coumarins alone in patients where no immediate anticoagulation effect is warranted [1, 3, 4]. Nevertheless, in clinical practice many physicians in Switzerland still tend to a concomitant use of a low-molecular-weight heparin (LMWH) when starting an anticoagulation treatment. This approach takes into consideration that there is a transient hypercoagulable state after starting a coumarin therapy, with the level of the vitamin K-dependent endogenous anticoagulation factor protein C dropping rapidly compared to the prothrombogenic Factors (e.g. IX, X and prothrombin) which leads to a transient procoagulant/anticoagulant imbalance that might in turn trigger thrombotic occlusion of small vessels followed by necrosis (coumarine necrosis) . The incidence of coumarine necrosis is not known, but is believed to range from 0.01 to 0.1% . It is a serious clinical condition leading to therapeutic problems and often requiring surgical intervention. On the other hand there is an increased risk for bleeding complications in patients simultaneously treated with LMWH and OAC and some patients report practical problems with the administration of LMWH. Moreover, there have been concerns about LMWH-induced skin necrosis and LMWH-induced thrombocytopenia . Based on the clinical observation, that the initiation regimens for OAC in outpatients with NVAF vary considerably, we conducted a survey aimed to assess current treatment practice in Switzerland. The purpose of our study was to assess the current practice regarding the initiation of OAC for NVAF in Switzerland, to determine the variables that influence guideline consistent treatment and to inquire whether initiation of anticoagulation is generally considered a clinical problem, as the latter might have an impact on the choice of e.g. a novel antithrombotic drug.
In 2009 we conducted a vignette-based survey on the initiation of oral anticoagulation with a postal questionnaire sent to selected physicians with various specialities in the canton of Zurich, Switzerland, a region that covers 1.4 million inhabitants. The study population was selected from physician databases provided by the local medical societies. The questionnaire was sent to a total of 388 physicians consisting of a random sample of general practitioners (n = 106), a random sample of the internists working in a medical practice (n = 93), as well as all the senior physicians working in a hospital department for internal medicine (n = 87) and all the cardiologists (n = 102). A postal reminder was sent 6 weeks after the initial questionnaire. The survey was based on voluntary participation. No financial incentives were provided by the investigators. Hence, no formal informed consent was obtained from the participating physicians. No ethical approval is required for this type of study.
We performed a cross-sectional vignette-based survey targeting 4 major objectives: to determine current anticoagulation regimens in out-patients with non-valvular atrial fibrillation (NVAF), to determine the prevalence of guideline conform initiation of oral anticoagulation (OAC), to evaluate possible determinants (physician characteristics, health care setting) of guideline conform OAC regimens and to determine, whether physicians consider initiation of OAC to be a problem in patient care. The vignette described an outpatient with non-valvular atrial fibrillation at high-risk for stroke (CHADS2-score ≥ 2) requiring long-term OAC treatment (Appendix)
A guideline conform initiation of anticoagulation was defined based on current recommendations as (A) starting with a low dose regimen of a vitamin K antagonist (VKA) or (B) the use of a VKA loading dose combined with low-molecular-weight heparin (LMWH) in a therapeutic dose. Physician characteristics and medical experience were assessed as follow: Demographics (age, sex), medical speciality (general practitioner, internist, cardiologist), practice setting (non-hospital vs. hospital setting), medical experience including the case load of NVAF in the previous 6 months and experienced adverse events related to the OAC initiation (e.g. bleeding, thromboembolism, skin necrosis). The frequency of using guidelines in general was additionally assessed semi-quantitatively (e.g. rarely, often, always).
Categorical data are presented as frequencies. Chi-square statistics were used to assess crude associations between physicians' characteristics and a guideline conform OAC initiation regimen and long-term OAC use, respectively. To further investigate the independent relationship between a guideline conform OAC use and the health care setting (e.g. hospital setting vs. ambulatory care) multiple logistic regression analysis was applied.
Of the 388 questionnaires a total of 226 (58.2%) were returned and could be further analyzed. Responding rates between the various specialists in ambulatory care and hospital physicians ranged between 47% for general practitioners (GP) and 65% for general internists (GI). Out of the 226 respondents the distribution of medical speciality was as followed: 56 (24.8%) primary care physicians, 120 (53.1%) general internists, and 50 (22.1%) cardiologists (CA). Seventy six (33.6%) out of the 226 physicians worked in hospital care. Most of the hospital physicians were specialist in internal medicine (72.4%), which explained the overall high proportion of general internists with the remaining being cardiologists (25%) and general practitioners (2.6%).
Physicians' characteristics, clinical practice and experience according to speciality and health care setting
N = 226
N = 150 (66.4%)
Hospital care N = 76 (33.6%)
(N = 54)
(N = 65)
(N = 31)
Male N (%)
Experience N (%)
- 5-10 years
- 10-15 years
- > 15 years
Case load (6 months)
- 1 - 5
- > 5
Use of Guidelines
Adverse events during OAC initiation
- reported N (% of physicians)
- skin necrosis
Hospitalists reported significantly more adverse events due to OAC compared to the various specialists working in an ambulatory setting (65.8 vs. 32.0%) (p < 0.05) (Table 1). Thromboembolism was the most prevalent adverse event reported followed by bleeding complications and skin necrosis due to OAC (Table 1).
OAC initiation regimens and guideline adherence according to speciality and health care setting
OAC initiation regimen N (%)
- OAC alone loading dose
- OAC alone
- OAC + LMWH prophylactic dose
- OAC + LMWH therapeutic dose
- OAC + Aspirin
- Aspirin alone
Guideline conform OAC initiation (%)
Long-term OAC regimen (%)
Adjusted associations between a guideline conform OAC initiation in relation to the health care setting
Model 1 (N = 221):
Model 2 (N = 219):
Adjusted associations between a long-term OAC regimen in relation to the health care setting
Model 1 (N = 221):
Model 2 (N = 219):
In the whole study sample problems when starting an anticoagulation treatment were seldom reported (never or seldom accounting for 94.1% of all responses). The cumulative prevalence of physicians reporting to often or always encounter problems related to the OAC initiation was significantly higher in the hospital setting (9.7%) compared to physicians in the ambulatory care setting (4.0%) (p for difference < 0.001).
The data of our survey confirm the expected variability in guideline adherence in respect to initiation of anticoagulation in non-valvular atrial fibrillation (NVAF), with health care setting rather than medical speciality being associated with a recommendation consistent treatment. The majority of the physicians does not consider the initiation of OAC to be a major problem in patient care.
The factors commonly influencing guideline adherence of physicians are well known and consist in (i) the quality of the data leading to the actual treatment recommendations, (ii) familiarity with the recommendations (iii) the physicians agreement with the recommendations, (iv) the expected impact of a therapeutic measure on the disease outcome (v) the patient population and (vi) organisational factors such as workload and convenience of the recommendations) [8, 9]. We discuss the results of our survey based on these key factors.
Quality of data: In NVAF there is an imbalance in the quality of the data leading to the actual treatment recommendations. While there are well-established scoring systems assessing the risk for stroke in NVAF (e.g. CHA2DS2-VASc and CHADS2) and an effective prophylaxis with the vitamin K antagonists (VKA) leading to a class IA recommendation for long-term VKA prophylaxis in high-risk patients with NVAF, data regarding the optimal initiation of OAC is sparse [1, 10–16]. E.g. there is no prospective trial comparing an OAC initiation regimen with and without concurrent heparin or low-molecular-weight heparin (LMWH) use. In addition, there is a lack of data on the incidence of heparin- and warfarin-induced skin necrosis and the occurrence of stroke when commencing an OAC prophylaxis, which leads to considerable uncertainty about the need for concurrent OAC and Heparin or LMWH. Therefore, recommendations are less stringent for OAC initiation but nevertheless, ACCP 2008 guidelines as well as BCSH 2005 guidelines do allow a low-dose VKA commencement without concurrent heparin or LMWH if no immediate anticoagulation effect is warranted [3, 4]. This difference in the quality of scientific data might be reflected by our study results which confirm a high theoretical adherence to guidelines in respect to long-term OAC (93.7%) whereas a correct initiation regimen defined as choosing either a low-dose VKA scheme or adding LMWH to a VKA loading dose scheme was chosen by only 60.6% of all participants. We did not find a difference in the adherence of long-term OAC across medical specialities. This is in line with McCrory and coworkers who addressed physicians attitudes on long-term OAC for stroke prophylaxis in different clinical scenarios by means of a case-vignette which revealed no difference between primary care physicians, cardiologists and neurologists . However we are not aware of studies that focused on the initiation of OAC in NVAF or the impact of the health care setting on this issue.
Familiarity and agreement with the recommendations: Another factor influencing guideline adherence is the knowledge of the recommendations themselves. An european study found, that cardiologists show a higher familiarity with heart failure guidelines when compared to internists, geriatricians, and primary care physicians . Our data is more conflicting as 90.3% of all cardiologists working in outpatient care reported to use guidelines for decision making but only 58.2% actually chose a guideline conform OAC initiation regimen. Moreover, our data does not show a significant difference between the various medical specialities with regard to guideline-consistent anticoagulation for stroke prophylaxis in NVAF. It is known from the literature that practicing physicians have an attitudinalbehavioral discordance concerning their positive perception of clinical practice guidelines and the implementation of these guidelines into their own clinical practice . Nevertheless, we can only hypothesize on the reasons for this imbalance in our cardiologist group: First, even though the cardiologists may usually be familiar with many guidelines, this might not be the case regarding this particular topic. Second, the physician might disagree with the guidelines and third, there might be a lack of outcome expectancy when adhering to the guidelines.
Outcome expectancy and patient selection: The hypothesis that the outcome expectancy and the patient selection might play an important role in clinical practice is supported by our data reporting a significant difference in guideline consistent behaviour, mainly depending on the health-care setting with hospital physicians showing a higher degree of guideline adherence than doctors in outpatient care. Patients with NVAF who have to be referred to a hospital are either relatively fit but will undergo cardioversion within 48 hours of onset or, which is more likely, represent a different patient subset with comorbidities or an acute condition leading to hospital admission . The latter has an impact on OAC, as e.g. anticoagulation dependent skin necrosis is known to only rarely occur in otherwise healthy outpatients treated for NVAF but is mainly observed in more severely ill hospitalized patients with comorbidities [6, 21–23]. Hence, doctors working in a hospital setting are exposed to a different patient population and more likely to be confronted with adverse events, an experience which might constrain them to a more guideline stringent behaviour . As a matter of fact, hospital physicians in our study reported a significantly higher number of adverse events during the initial phase of a OAC treatment. In contrast, physicians working in a private practice claim to observe adverse events only in a minority of cases which might lessen the need for guidelines as they are not believed to significantly influence disease outcome.
The generally low use of guidelines in the general practitioner fraction is also noteworthy. We hypothesize that beside the difficulty in keeping up with a high level of knowledge in a large and heterogenous medical field, this might also be due to the high prevalence of multimorbide patients seen in family practice . Physicians caring for multimorbide patients might consider it less reasonable to implement a therapeutical strategy solely based on the summation of single-disease recommendations as this will be far to comprehensive and might even proof to be harmful in this context [25, 26].
First, the design of our study is a limitating factor as all observational studies always lack the power to proof causality. Second, even though our survey shows a high return rate of 58% and is therefore clearly representative for the clinical practice in an urban area in Switzerland, its results might not apply for other countries as e.g. in Switzerland the VKA of choice for patients with NVAF is phrenprocoumon which has a much longer elimination half life when compared to warfarin (140 vs. 40 hours). Most international trials are based on a VKA treatment with warfarin and even though the results might not differ substantially from a treatment with other VKAs, the conclusions obtained from a study with warfarin can, strictly spoken, not be translated to other treatment modalities. Third, a survey always assesses a theoretical adherence to therapies or treatment recommendations and despite the fact, that the majority of doctors might be familiar with current guidelines, they might not consequently translate them into clinical practice. In an observational study conducted in Basel, Switzerland, 31% of all patients with atrial fibrillation who qualified for an oral anticoagulation did not receive a VKA . This finding is supported by data from many different regions worldwide .
Our present study shows how physicians intend to start stroke prophylaxis in outpatients with NVAF in an urban region in Switzerland. Whilst the theoretical knowledge of the correct long-term treatment for these patients is excellent, compliance to guidelines with respect to the initiation of anticoagulation is not. There is a difference in guideline adherence based on the clinical setting, with hospital physicians showing a better guideline adherence when compared to their colleagues in outpatient care. Further studies are needed to address this issue and detect possible causes. We hypothesize that patient selection, outcome expectancy, and familiarity with guidelines might account for a good part of this difference. However, as with the introduction of any practice guideline, physicians need to be convinced that there exists compelling evidence from well-controlled clinical trials to justify implementation of these recommendations to the individual patient.
We are grateful for logistic assistance provided by A. Schickel, and B. Portner, Insitute of General Practice and Health Services Research, University of Zurich.
- Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, Manning WJ: Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008, 133 (6 Suppl): 546S-592S. 10.1378/chest.08-0678. 8View ArticlePubMedGoogle Scholar
- Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, et al: ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006, 114 (7): e257-354.View ArticlePubMedGoogle Scholar
- Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G: Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008, 133 (6 Suppl): 160S-198S. 10.1378/chest.08-0670. 8View ArticlePubMedGoogle Scholar
- Baglin TP, Keeling DM, Watson HG: Guidelines on oral anticoagulation (warfarin): third edition-2005 update. Br J Haematol. 2006, 132 (3): 277-285. 10.1111/j.1365-2141.2005.05856.x.View ArticlePubMedGoogle Scholar
- Stirling Y: Warfarin-induced changes in procoagulant and anticoagulant proteins. Blood Coagul Fibrinolysis. 1995, 6 (5): 361-373. 10.1097/00001721-199507000-00001.View ArticlePubMedGoogle Scholar
- Sallah S, Thomas DP, Roberts HR: Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment. Thromb Haemost. 1997, 78 (2): 785-790.PubMedGoogle Scholar
- Handschin AE, Trentz O, Kock HJ, Wanner GA: Low molecular weight heparin-induced skin necrosis-a systematic review. Langenbecks Arch Surg. 2005, 390 (3): 249-254. 10.1007/s00423-004-0522-7.View ArticlePubMedGoogle Scholar
- Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR: Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999, 282 (15): 1458-1465. 10.1001/jama.282.15.1458.View ArticlePubMedGoogle Scholar
- Carlsen B, Glenton C, Pope C: Thou shalt versus thou shalt not: a meta-synthesis of GPs' attitudes to clinical practice guidelines. Br J Gen Pract. 2007, 57 (545): 971-978. 10.3399/096016407782604820.View ArticlePubMedPubMed CentralGoogle Scholar
- Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001, 285 (22): 2864-2870. 10.1001/jama.285.22.2864.View ArticlePubMedGoogle Scholar
- Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999, 131 (7): 492-501.View ArticlePubMedGoogle Scholar
- van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B: Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002, 288 (19): 2441-2448. 10.1001/jama.288.19.2441.View ArticlePubMedGoogle Scholar
- Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ: Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010, 137 (2): 263-272. 10.1378/chest.09-1584.View ArticlePubMedGoogle Scholar
- Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, et al: Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011, 342: d124-10.1136/bmj.d124.View ArticlePubMedPubMed CentralGoogle Scholar
- Janes S, Challis R, Fisher F: Safe introduction of warfarin for thrombotic prophylaxis in atrial fibrillation requiring only a weekly INR. Clin Lab Haematol. 2004, 26 (1): 43-47. 10.1111/j.0141-9854.2003.00579.x.View ArticlePubMedGoogle Scholar
- Oates A, Jackson PR, Austin CA, Channer KS: A new regimen for starting warfarin therapy in out-patients. Br J Clin Pharmacol. 1998, 46 (2): 157-161.View ArticlePubMedPubMed CentralGoogle Scholar
- McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL: Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med. 1995, 155 (3): 277-281. 10.1001/archinte.1995.00430030071008.View ArticlePubMedGoogle Scholar
- Remme WJ, McMurray JJ, Hobbs FD, Cohen-Solal A, Lopez-Sendon J, Boccanelli A, Zannad F, Rauch B, Keukelaar K, Macarie C, et al: Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. Eur Heart J. 2008, 29 (14): 1739-1752. 10.1093/eurheartj/ehn196.View ArticlePubMedGoogle Scholar
- Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ: Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med. 1989, 321 (19): 1306-1311. 10.1056/NEJM198911093211906.View ArticlePubMedGoogle Scholar
- Stewart FM, Singh Y, Persson S, Gamble GD, Braatvedt GD: Atrial fibrillation: prevalence and management in an acute general medical unit. Aust N Z J Med. 1999, 29 (1): 51-58. 10.1111/j.1445-5994.1999.tb01588.x.View ArticlePubMedGoogle Scholar
- Griffin JP: Anticoagulants and skin necrosis. Adverse Drug React Toxicol Rev. 1994, 13 (3): 157-167.PubMedGoogle Scholar
- Comp PC: Coumarin-induced skin necrosis. Incidence, mechanisms, management and avoidance. Drug Saf. 1993, 8 (2): 128-135. 10.2165/00002018-199308020-00003.View ArticlePubMedGoogle Scholar
- Jorg I, Fenyvesi T, Harenberg J: Anticoagulant-related skin reactions. Expert Opin Drug Saf. 2002, 1 (3): 287-294. 10.1517/147403220.127.116.117.View ArticlePubMedGoogle Scholar
- Fortin M, Bravo G, Hudon C, Vanasse A, Lapointe L: Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med. 2005, 3 (3): 223-228. 10.1370/afm.272.View ArticlePubMedPubMed CentralGoogle Scholar
- Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW: Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005, 294 (6): 716-724. 10.1001/jama.294.6.716.View ArticlePubMedGoogle Scholar
- Greenfield S, Billimek J, Pellegrini F, Franciosi M, De Berardis G, Nicolucci A, Kaplan SH: Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Intern Med. 2009, 151 (12): 854-860.View ArticlePubMedGoogle Scholar
- Zehnder BS, Schaer BA, Jeker U, Cron TA, Osswald S: Atrial fibrillation: estimated excess rate of stroke due to lacking adherence to guidelines. Swiss Med Wkly. 2006, 136 (47-48): 757-760.PubMedGoogle Scholar
- Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY: Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010, 123 (7): 638-645. 10.1016/j.amjmed.2009.11.025. e634View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2261/12/12/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.